Insulet Corporation $PODD Holdings Lifted by Eversept Partners LP

Eversept Partners LP increased its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 63.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 74,708 shares of the medical instruments supplier’s stock after purchasing an additional 29,104 shares during the quarter. Insulet makes up 1.1% of Eversept Partners LP’s investment portfolio, making the stock its 22nd largest position. Eversept Partners LP’s holdings in Insulet were worth $21,235,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Insulet by 1.0% in the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after purchasing an additional 87,845 shares in the last quarter. State Street Corp grew its stake in Insulet by 2.1% in the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after purchasing an additional 65,317 shares in the last quarter. Geode Capital Management LLC grew its stake in Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after purchasing an additional 41,019 shares in the last quarter. Norges Bank purchased a new position in Insulet in the fourth quarter valued at about $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Insulet by 3.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock valued at $229,131,000 after purchasing an additional 29,690 shares in the last quarter.

Insulet Price Performance

NASDAQ PODD opened at $143.52 on Thursday. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The stock has a market capitalization of $9.94 billion, a PE ratio of 33.38, a P/E/G ratio of 1.16 and a beta of 1.13. The stock has a 50-day simple moving average of $166.47 and a 200 day simple moving average of $228.11.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s revenue was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts anticipate that Insulet Corporation will post 6.46 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on PODD. The Goldman Sachs Group restated a “buy” rating and issued a $205.00 target price on shares of Insulet in a research note on Wednesday, May 27th. Jefferies Financial Group lowered their target price on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Royal Bank Of Canada restated an “outperform” rating and issued a $280.00 target price on shares of Insulet in a research note on Wednesday, May 27th. Wall Street Zen upgraded Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, William Blair began coverage on Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating on the stock. Twenty-one research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $240.78.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.36% of the stock is currently owned by company insiders.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.